---
document_datetime: 2025-12-29 12:21:49
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/zarzio.html
document_name: zarzio.html
version: success
processing_time: 0.1102842
conversion_datetime: 2025-12-30 09:56:35.74723
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Zarzio

[RSS](/en/individual-human-medicine.xml/66121)

##### Authorised

This medicine is authorised for use in the European Union

filgrastim Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [Related content](#related-content-619)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach its recommendations on how to use the medicine.

If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis of the CHMP recommendations, read the scientific discussion (also part of the EPAR).

Expand section

Collapse section

## What is Zarzio?

Zarzio is a solution for injection or infusion (drip into a vein) in a prefilled syringe. It contains the active substance filgrastim (30 or 48 million units).

Zarzio is a 'biosimilar medicine'. This means that Zarzio is similar to a biological medicine that is already authorised in the European Union (EU) and contains the same active substance (also known as the 'reference medicine'). The reference medicine for Zarzio is Neupogen.

## What is Zarzio used for?

Zarzio is used to stimulate the production of white blood cells in the following situations:

- to reduce the duration of neutropenia (low levels of neutrophils, a type of white blood cell) and the occurrence of febrile neutropenia (neutropenia with fever) in patients receiving chemotherapy (cancer treatment) that is cytotoxic (cell-killing);
- to reduce the duration of neutropenia in patients undergoing treatment to destroy the bone marrow cells before a bone-marrow transplant (such as in some patients with leukaemia) if they are at a risk of long-term, severe neutropenia;
- to increase levels of neutrophils and reduce the risk of infections in patients with neutropenia who have a history of severe, repeated infections;
- to treat persistent neutropenia in patients with advanced human-immunodeficiency-virus (HIV) infection, to reduce the risk of bacterial infections when other treatments are not appropriate.

Zarzio can also be used in people who are about to donate blood stem cells for transplant, to help release these cells from the bone marrow. The medicine can only be obtained with a prescription.

## How is Zarzio used?

Zarzio is given by injection under the skin or infusion into a vein. How it is given, the dose and the duration of treatment depend on why it is being used, the patient's body weight and the response to treatment. Zarzio is usually given in a specialised treatment centre, although patients who receive it by injection under the skin may inject themselves once they have been trained appropriately. For more information, see the package leaflet.

## How does Zarzio work?

The active substance in Zarzio, filgrastim, is very similar to a human protein called granulocyte colony stimulating factor (G-CSF). Filgrastim is produced by a method known as 'recombinant DNA technology': it is made by a bacterium that has received a gene (DNA), which makes it able to produce filgrastim. The replacement acts in the same way as naturally produced G-CSF by encouraging the bone marrow to produce more white blood cells.

## How has Zarzio been studied?

Zarzio was studied to show that it is comparable to the reference medicine, Neupogen.

Four studies looked at the levels of neutrophils in the blood in a total of 146 healthy volunteers who received Zarzio or Neupogen. The studies looked at the effects of single and repeated administration of various doses of the medicines, either injected under the skin or infused into a vein. The main measure in these studies was the neutrophil count over the first 10 days of treatment.

## What benefit has Zarzio shown during the studies?

Zarzio and Neupogen brought about similar increases in blood neutrophil counts in healthy volunteers over the course of the studies. This was considered sufficient to demonstrate that the benefits of Zarzio are comparable to those of the reference medicine.

## What is the risk associated with Zarzio?

The most common side effect with Zarzio (seen in more than 1 patient in 10) is musculoskeletal pain (pain in the muscles and bones). Other side effects may be seen in more than 1 patient in 10, depending on the condition that Zarzio is being used for. For the full list of all side effects reported with Zarzio, see the package leaflet.

Zarzio should not be used in people who may be hypersensitive (allergic) to filgrastim or any of the other ingredients.

## Why has Zarzio been approved?

The Committee for Medicinal Products for Human Use (CHMP) decided that, in accordance with EU requirements, Zarzio has been shown to have a comparable quality, safety and efficacy profile to Neupogen. Therefore, the CHMP's view was that, as for Neupogen, the benefit outweighs the identified risk. The Committee recommended that Zarzio be given marketing authorisation.

## Other information about Zarzio

The European Commission granted a marketing authorisation valid throughout the EU for Zarzio to Sandoz GmbH on 6 February 2009.

Zarzio : EPAR - Summary for the public

English (EN) (80.43 KB - PDF)

**First published:** 17/02/2009

**Last updated:** 17/02/2009

[View](/en/documents/overview/zarzio-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-3)

български (BG) (133.76 KB - PDF)

**First published:**

17/02/2009

**Last updated:**

17/02/2009

[View](/bg/documents/overview/zarzio-epar-summary-public_bg.pdf)

español (ES) (82.59 KB - PDF)

**First published:**

17/02/2009

**Last updated:**

17/02/2009

[View](/es/documents/overview/zarzio-epar-summary-public_es.pdf)

čeština (CS) (130.71 KB - PDF)

**First published:**

17/02/2009

**Last updated:**

17/02/2009

[View](/cs/documents/overview/zarzio-epar-summary-public_cs.pdf)

dansk (DA) (80.71 KB - PDF)

**First published:**

17/02/2009

**Last updated:**

17/02/2009

[View](/da/documents/overview/zarzio-epar-summary-public_da.pdf)

Deutsch (DE) (82.31 KB - PDF)

**First published:**

17/02/2009

**Last updated:**

17/02/2009

[View](/de/documents/overview/zarzio-epar-summary-public_de.pdf)

eesti keel (ET) (79.33 KB - PDF)

**First published:**

17/02/2009

**Last updated:**

17/02/2009

[View](/et/documents/overview/zarzio-epar-summary-public_et.pdf)

ελληνικά (EL) (111.38 KB - PDF)

**First published:**

17/02/2009

**Last updated:**

17/02/2009

[View](/el/documents/overview/zarzio-epar-summary-public_el.pdf)

français (FR) (83.18 KB - PDF)

**First published:**

17/02/2009

**Last updated:**

17/02/2009

[View](/fr/documents/overview/zarzio-epar-summary-public_fr.pdf)

hrvatski (HR) (102.33 KB - PDF)

**First published:**

17/02/2009

**Last updated:**

17/02/2009

[View](/hr/documents/overview/zarzio-epar-summary-public_hr.pdf)

italiano (IT) (80.03 KB - PDF)

**First published:**

17/02/2009

**Last updated:**

17/02/2009

[View](/it/documents/overview/zarzio-epar-summary-public_it.pdf)

latviešu valoda (LV) (104.95 KB - PDF)

**First published:**

17/02/2009

**Last updated:**

17/02/2009

[View](/lv/documents/overview/zarzio-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (105.65 KB - PDF)

**First published:**

17/02/2009

**Last updated:**

17/02/2009

[View](/lt/documents/overview/zarzio-epar-summary-public_lt.pdf)

magyar (HU) (103.47 KB - PDF)

**First published:**

17/02/2009

**Last updated:**

17/02/2009

[View](/hu/documents/overview/zarzio-epar-summary-public_hu.pdf)

Malti (MT) (108.51 KB - PDF)

**First published:**

17/02/2009

**Last updated:**

17/02/2009

[View](/mt/documents/overview/zarzio-epar-summary-public_mt.pdf)

Nederlands (NL) (82.19 KB - PDF)

**First published:**

17/02/2009

**Last updated:**

17/02/2009

[View](/nl/documents/overview/zarzio-epar-summary-public_nl.pdf)

polski (PL) (106.79 KB - PDF)

**First published:**

17/02/2009

**Last updated:**

17/02/2009

[View](/pl/documents/overview/zarzio-epar-summary-public_pl.pdf)

português (PT) (81.15 KB - PDF)

**First published:**

17/02/2009

**Last updated:**

17/02/2009

[View](/pt/documents/overview/zarzio-epar-summary-public_pt.pdf)

română (RO) (103.62 KB - PDF)

**First published:**

17/02/2009

**Last updated:**

17/02/2009

[View](/ro/documents/overview/zarzio-epar-summary-public_ro.pdf)

slovenčina (SK) (105.13 KB - PDF)

**First published:**

17/02/2009

**Last updated:**

17/02/2009

[View](/sk/documents/overview/zarzio-epar-summary-public_sk.pdf)

slovenščina (SL) (102.61 KB - PDF)

**First published:**

17/02/2009

**Last updated:**

17/02/2009

[View](/sl/documents/overview/zarzio-epar-summary-public_sl.pdf)

Suomi (FI) (79.57 KB - PDF)

**First published:**

17/02/2009

**Last updated:**

17/02/2009

[View](/fi/documents/overview/zarzio-epar-summary-public_fi.pdf)

svenska (SV) (80.69 KB - PDF)

**First published:**

17/02/2009

**Last updated:**

17/02/2009

[View](/sv/documents/overview/zarzio-epar-summary-public_sv.pdf)

Zarzio : EPAR - Risk-management-plan summary

English (EN) (60.09 KB - PDF)

**First published:** 30/01/2023

[View](/en/documents/rmp-summary/zarzio-epar-risk-management-plan-summary_en.pdf)

## Product information

Zarzio : EPAR - Product Information

English (EN) (1.09 MB - PDF)

**First published:** 09/11/2009

**Last updated:** 08/07/2025

[View](/en/documents/product-information/zarzio-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-506)

български (BG) (952.96 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

08/07/2025

[View](/bg/documents/product-information/zarzio-epar-product-information_bg.pdf)

español (ES) (992.36 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

08/07/2025

[View](/es/documents/product-information/zarzio-epar-product-information_es.pdf)

čeština (CS) (740.19 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

08/07/2025

[View](/cs/documents/product-information/zarzio-epar-product-information_cs.pdf)

dansk (DA) (901 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

08/07/2025

[View](/da/documents/product-information/zarzio-epar-product-information_da.pdf)

Deutsch (DE) (938.69 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

08/07/2025

[View](/de/documents/product-information/zarzio-epar-product-information_de.pdf)

eesti keel (ET) (809.19 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

08/07/2025

[View](/et/documents/product-information/zarzio-epar-product-information_et.pdf)

ελληνικά (EL) (1023.1 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

08/07/2025

[View](/el/documents/product-information/zarzio-epar-product-information_el.pdf)

français (FR) (913.2 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

08/07/2025

[View](/fr/documents/product-information/zarzio-epar-product-information_fr.pdf)

hrvatski (HR) (972.35 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

08/07/2025

[View](/hr/documents/product-information/zarzio-epar-product-information_hr.pdf)

íslenska (IS) (813.51 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

08/07/2025

[View](/is/documents/product-information/zarzio-epar-product-information_is.pdf)

italiano (IT) (1009.35 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

08/07/2025

[View](/it/documents/product-information/zarzio-epar-product-information_it.pdf)

latviešu valoda (LV) (978.01 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

08/07/2025

[View](/lv/documents/product-information/zarzio-epar-product-information_lv.pdf)

lietuvių kalba (LT) (898.73 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

08/07/2025

[View](/lt/documents/product-information/zarzio-epar-product-information_lt.pdf)

magyar (HU) (1 MB - PDF)

**First published:**

09/11/2009

**Last updated:**

08/07/2025

[View](/hu/documents/product-information/zarzio-epar-product-information_hu.pdf)

Malti (MT) (1017.66 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

08/07/2025

[View](/mt/documents/product-information/zarzio-epar-product-information_mt.pdf)

Nederlands (NL) (917.9 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

08/07/2025

[View](/nl/documents/product-information/zarzio-epar-product-information_nl.pdf)

norsk (NO) (825.08 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

08/07/2025

[View](/no/documents/product-information/zarzio-epar-product-information_no.pdf)

polski (PL) (1.02 MB - PDF)

**First published:**

09/11/2009

**Last updated:**

08/07/2025

[View](/pl/documents/product-information/zarzio-epar-product-information_pl.pdf)

português (PT) (842.19 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

08/07/2025

[View](/pt/documents/product-information/zarzio-epar-product-information_pt.pdf)

română (RO) (1000.32 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

08/07/2025

[View](/ro/documents/product-information/zarzio-epar-product-information_ro.pdf)

slovenčina (SK) (748.37 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

08/07/2025

[View](/sk/documents/product-information/zarzio-epar-product-information_sk.pdf)

slovenščina (SL) (911.66 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

08/07/2025

[View](/sl/documents/product-information/zarzio-epar-product-information_sl.pdf)

Suomi (FI) (829.24 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

08/07/2025

[View](/fi/documents/product-information/zarzio-epar-product-information_fi.pdf)

svenska (SV) (927.03 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

08/07/2025

[View](/sv/documents/product-information/zarzio-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** WS2770 20/03/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Zarzio : EPAR - All Authorised presentations

English (EN) (84.57 KB - PDF)

**First published:** 16/02/2009

**Last updated:** 12/01/2023

[View](/en/documents/all-authorised-presentations/zarzio-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-816)

български (BG) (121.89 KB - PDF)

**First published:**

16/02/2009

**Last updated:**

12/01/2023

[View](/bg/documents/all-authorised-presentations/zarzio-epar-all-authorised-presentations_bg.pdf)

español (ES) (110.49 KB - PDF)

**First published:**

16/02/2009

**Last updated:**

12/01/2023

[View](/es/documents/all-authorised-presentations/zarzio-epar-all-authorised-presentations_es.pdf)

čeština (CS) (150.01 KB - PDF)

**First published:**

16/02/2009

**Last updated:**

12/01/2023

[View](/cs/documents/all-authorised-presentations/zarzio-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (110.8 KB - PDF)

**First published:**

16/02/2009

**Last updated:**

12/01/2023

[View](/da/documents/all-authorised-presentations/zarzio-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (114.35 KB - PDF)

**First published:**

16/02/2009

**Last updated:**

12/01/2023

[View](/de/documents/all-authorised-presentations/zarzio-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (106.68 KB - PDF)

**First published:**

16/02/2009

**Last updated:**

12/01/2023

[View](/et/documents/all-authorised-presentations/zarzio-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (138.24 KB - PDF)

**First published:**

16/02/2009

**Last updated:**

12/01/2023

[View](/el/documents/all-authorised-presentations/zarzio-epar-all-authorised-presentations_el.pdf)

français (FR) (108.89 KB - PDF)

**First published:**

16/02/2009

**Last updated:**

12/01/2023

[View](/fr/documents/all-authorised-presentations/zarzio-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (99.74 KB - PDF)

**First published:**

16/02/2009

**Last updated:**

12/01/2023

[View](/hr/documents/all-authorised-presentations/zarzio-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (110.11 KB - PDF)

**First published:**

16/02/2009

**Last updated:**

12/01/2023

[View](/is/documents/all-authorised-presentations/zarzio-epar-all-authorised-presentations_is.pdf)

italiano (IT) (106.99 KB - PDF)

**First published:**

16/02/2009

**Last updated:**

12/01/2023

[View](/it/documents/all-authorised-presentations/zarzio-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (149.07 KB - PDF)

**First published:**

16/02/2009

**Last updated:**

12/01/2023

[View](/lv/documents/all-authorised-presentations/zarzio-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (147.28 KB - PDF)

**First published:**

16/02/2009

**Last updated:**

12/01/2023

[View](/lt/documents/all-authorised-presentations/zarzio-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (157.87 KB - PDF)

**First published:**

16/02/2009

**Last updated:**

12/01/2023

[View](/hu/documents/all-authorised-presentations/zarzio-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (161.75 KB - PDF)

**First published:**

16/02/2009

**Last updated:**

12/01/2023

[View](/mt/documents/all-authorised-presentations/zarzio-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (108.33 KB - PDF)

**First published:**

16/02/2009

**Last updated:**

12/01/2023

[View](/nl/documents/all-authorised-presentations/zarzio-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (112.45 KB - PDF)

**First published:**

16/02/2009

**Last updated:**

12/01/2023

[View](/no/documents/all-authorised-presentations/zarzio-epar-all-authorised-presentations_no.pdf)

polski (PL) (161.29 KB - PDF)

**First published:**

16/02/2009

**Last updated:**

12/01/2023

[View](/pl/documents/all-authorised-presentations/zarzio-epar-all-authorised-presentations_pl.pdf)

português (PT) (111.58 KB - PDF)

**First published:**

16/02/2009

**Last updated:**

12/01/2023

[View](/pt/documents/all-authorised-presentations/zarzio-epar-all-authorised-presentations_pt.pdf)

română (RO) (149.45 KB - PDF)

**First published:**

16/02/2009

**Last updated:**

12/01/2023

[View](/ro/documents/all-authorised-presentations/zarzio-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (152.83 KB - PDF)

**First published:**

16/02/2009

**Last updated:**

12/01/2023

[View](/sk/documents/all-authorised-presentations/zarzio-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (150.36 KB - PDF)

**First published:**

16/02/2009

**Last updated:**

12/01/2023

[View](/sl/documents/all-authorised-presentations/zarzio-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (105.78 KB - PDF)

**First published:**

16/02/2009

**Last updated:**

12/01/2023

[View](/fi/documents/all-authorised-presentations/zarzio-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (106.95 KB - PDF)

**First published:**

16/02/2009

**Last updated:**

12/01/2023

[View](/sv/documents/all-authorised-presentations/zarzio-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Zarzio Active substance filgrastim International non-proprietary name (INN) or common name filgrastim Therapeutic area (MeSH)

- Hematopoietic Stem Cell Transplantation
- Cancer

Anatomical therapeutic chemical (ATC) code L03AA02

### Pharmacotherapeutic group

Immunostimulants

### Therapeutic indication

- Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone-marrow transplantation considered to be at increased risk of prolonged severe neutropenia. The safety and efficacy of filgrastim are similar in adults and children receiving cytotoxic chemotherapy.
- Mobilisation of peripheral blood progenitor cells (PBPC).
- In children and adults with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of ?0.5 x 10 9 /l, and a history of severe or recurrent infections, long term administration of filgrastim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.
- Treatment of persistent neutropenia (ANC ? 1.0 x 10 9 /l) in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other therapeutic options are inappropriate.

## Authorisation details

EMA product number EMEA/H/C/000917

Biosimilar

This is a biosimilar medicine, which is a biological medicine highly similar to another already approved biological medicine called the 'reference medicine'. For more information, see [Biosimilar medicines](/node/68323) .

Marketing authorisation holder

Sandoz GmbH

Biochemiestrasse 10

Marketing authorisation issued 06/02/2009 Revision 27

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Zarzio : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (291.48 KB - PDF)

**First published:** 09/11/2009

**Last updated:** 08/07/2025

[View](/en/documents/procedural-steps-after/zarzio-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Zarzio - EMEA/H/C/000917 &amp; 918/P46/022 : EPAR - Assessment report

Reference Number: EMA/210565/2021

English (EN) (435.26 KB - PDF)

**First published:** 24/06/2021

**Last updated:** 24/06/2021

[View](/en/documents/variation-report/zarzio-emeahc000917-918p46022-epar-assessment-report_en.pdf)

## Initial marketing authorisation documents

Zarzio : EPAR - Public assessment report

English (EN) (512.08 KB - PDF)

**First published:** 16/02/2009

**Last updated:** 16/02/2009

[View](/en/documents/assessment-report/zarzio-epar-public-assessment-report_en.pdf)

Committee for medicinal products for human use  summary of positive opinion  for Zarzio

Reference Number: EMEA/CHMP/574426/2008

English (EN) (82.32 KB - PDF)

**First published:** 20/11/2008

**Last updated:** 20/11/2008

[View](/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-zarzio_en.pdf)

#### Related content

- [Biosimilar medicines](/en/human-regulatory/overview/biosimilar-medicines)

#### Topics

- [Biosimilars](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A45)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 08/07/2025

## Share this page

[Back to top](#main-content)